Plasma-Derived ApoA-1

Man experiencing chest pain

Findings suggest CSL112 can boost cholesterol efflux capacity in patients with impaired endogenous HDL function. Encouragingly, several studies have documented its ability to reduce atherosclerotic plaque volume.

First Therapy Approved to Treat Rare Blood Clotting Disorder

Photo of vials of blood samples in a lab.

FDA has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive
therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura.